summit astrazeneca - Search News

News

AstraZeneca, Lung cancer and Summit

Reuters on MSN · 2d

Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with the matter.

Medical Dialogues · 12h

AstraZeneca, Summit in discussions over USD 15 billion cancer drug licensing deal: Report

Bengaluru: AstraZeneca is reportedly in discussions with Summit Therapeutics to license an experimental lung cancer drug in a deal that could be worth up to USD 15 billion, according to a

AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ivonescimab.

1d

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

1don MSN

Why AstraZeneca Stock Got Thumped on Thursday

A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...

Summit climbs on rumour of $15bn AstraZeneca interest

Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results